- Home
- GEN vs GMAB Comparison
GEN vs GMAB Comparison
Compare GEN & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEN
- GMAB
- Stock Information
- Founded
- GEN 1982
- GMAB 1999
- Country
- GEN United States
- GMAB Denmark
- Employees
- GEN 3500
- GMAB N/A
- Industry
- GEN Computer Software: Prepackaged Software
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- GEN Technology
- GMAB Health Care
- Exchange
- GEN Nasdaq
- GMAB Nasdaq
- Market Cap
- GEN 17.5B
- GMAB 12.8B
- IPO Year
- GEN N/A
- GMAB N/A
- Fundamental
- Price
- GEN $28.48
- GMAB $20.95
- Analyst Decision
- GEN Buy
- GMAB Buy
- Analyst Count
- GEN 4
- GMAB 9
- Target Price
- GEN $28.50
- GMAB $39.17
- AVG Volume (30 Days)
- GEN 5.6M
- GMAB 1.5M
- Earning Date
- GEN 05-06-2025
- GMAB 05-08-2025
- Dividend Yield
- GEN 1.76%
- GMAB N/A
- EPS Growth
- GEN 8.42
- GMAB 276.13
- EPS
- GEN 1.03
- GMAB 18.36
- Revenue
- GEN $3,935,000,000.00
- GMAB $3,230,902,140.00
- Revenue This Year
- GEN $21.98
- GMAB $17.69
- Revenue Next Year
- GEN $4.81
- GMAB $14.81
- P/E Ratio
- GEN $27.65
- GMAB $11.30
- Revenue Growth
- GEN 3.55
- GMAB 25.21
- 52 Week Low
- GEN $22.74
- GMAB $17.24
- 52 Week High
- GEN $31.72
- GMAB $28.96
- Technical
- Relative Strength Index (RSI)
- GEN 60.31
- GMAB 55.72
- Support Level
- GEN $27.78
- GMAB $20.73
- Resistance Level
- GEN $28.31
- GMAB $21.42
- Average True Range (ATR)
- GEN 0.50
- GMAB 0.45
- MACD
- GEN -0.08
- GMAB 0.11
- Stochastic Oscillator
- GEN 49.03
- GMAB 81.62
About GEN Gen Digital Inc.
Gen is a cybersecurity pure-play that offers security, identity protection, and privacy solutions to individual consumers. The firm's cyber safety offerings, via brands such as Norton, Avast, and LifeLock, have long maintained their positions as some of the most recognizable consumer-focused security and identity-protection products.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.